TME Pharma Extends Loans by 12 Months and Secures Cash Flow Until 2027
TME Pharma announces in a press release that certain lenders have agreed to extend the duration of their loans by an additional 12 months, ensuring its cash flow until the second quarter of 2027. This extension concerns about 93% of the loans taken out in May and August 2025.
Agreement Reached with Lenders
An agreement has been reached with lenders who participated in the May and August 2025 funding rounds to extend the duration of their loan contracts by an additional 12 months, bringing the total amount to approximately 2.06 million euros. In exchange for this extension, the duration of the warrants has been extended until December 31, 2030. Lenders received 30% additional warrants at the same exercise prices as the existing ones (0.10 € and 0.11 € respectively). These new warrants are subject to a lock-up period until January 1, 2029, unless the share price reaches or exceeds 0.25 €. TME Pharma will also repurchase the bonds from holders who do not wish to extend their duration for an amount of 163,562.50 € including interest.
Strategic Restructuring Under New CEO
Under the leadership of the new CEO, Diede van den Ouden, who joined in June 2025, TME Pharma is undergoing a strategic restructuring aimed at freeing up financial resources necessary to unlock the value of its two main assets, NOX-A12 and NOX-E36. The management states that they can now accelerate discussions with their partners to optimize the value of these compounds. No new warrants issued from the May and August 2025 programs have been exercised to date, and no new shares have been issued in 2025 and 2026.
